UnknownPhase NA

Anti-diabetic Drugs and Fatty Liver Management

Efficacy of Vildagliptin, Liraglutide and Empagliflozin in the Management of Fatty Liver Disease Among Patients With Type 2 Diabetes

Lead sponsor

Alexandria University

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

Estimated enrollment

120

Study population

MASH / NAFLD / liver fibrosis, Type 2 diabetes

Eligibility highlights

•HbA1c ≤10%

Primary endpoint

•Steatosis as measured

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05041673

Org study ID0304932

Timeline

Milestones

Study start2021-02-23actual

Study first posted2021-09-13actual

Primary completion2021-09-30actual

Last update posted2022-01-18actual

Study completion2022-09-30estimated

Assets

Investigational agents

Liraglutide

Who this study enrolls

MASH / NAFLD / liver fibrosisType 2 diabetes

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Type 2 DM with fatty liver disease.

•HbA1C less than 10.

Exclusion criteria

1. Alcohol intake.

2. BMI 40 or more.

3. CKD with e GFR less than 60.

4. chronic liver diseases (chronic viral hepatitis, autoimmune hepatitis, Wilson's disease, hemochromatosis, alfa-1 antitrypsin deficiency)

5. Atherosclerotic cardiovascular disease.

6. Celiac disease.

7. Clinically evident liver cirrhosis.

8. Patients who have ever had medullary thyroid carcinoma (MTC) or who have a family member who has ever had and patients who have multiple endocrine neoplasia syndrome type 2 (MEN 2)

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

MASH / liver

3 endpoints

Primary/protocol endpoint

Change in steatosis as measured using CAP score (fibroscan) and MRI

Time frame:12 months

change from baseline, improvement

Secondary/protocol endpoint

Change in liver enzymes

Time frame:12 months

change from baseline, improvement

Secondary/protocol endpoint

Changes in fibrosis grade

Time frame:12 months

Liver stiffness (VCTE), change

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.